AR060788A1 -
USE OF ELF -5A SPECIFIC APOPTOSIS SIARN TO DECREASE THE EXPRESSION OF PROINFLAMATORY CITOCINES FOR THE TREATMENT OF SEPSIS
- Google Patents
USE OF ELF -5A SPECIFIC APOPTOSIS SIARN TO DECREASE THE EXPRESSION OF PROINFLAMATORY CITOCINES FOR THE TREATMENT OF SEPSIS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senesco Technologies IncfiledCriticalSenesco Technologies Inc
Publication of AR060788A1publicationCriticalpatent/AR060788A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
La presente se refiere al factor de iniciacion eucariotico específico de apoptosis 5A (eIF-5A), o mencionado como eIF-5A específica de apoptosis o eIF5-A1, ácidos nucleicos y polipéptidos y métodos para reducir las citocinas pro-inflamatorias en un mamífero mediante la administracion de siARN contra eIF- al mamífero a fin de tratar/prevenir la sepsis y/o shock hemorrágico.This refers to the eukaryotic initiation factor specific for apoptosis 5A (eIF-5A), or referred to as eIF-5A specific for apoptosis or eIF5-A1, nucleic acids and polypeptides and methods for reducing pro-inflammatory cytokines in a mammal by the administration of siRNA against eIF- to the mammal in order to treat / prevent sepsis and / or hemorrhagic shock.
ARP070101974A2006-05-082007-05-07
USE OF ELF -5A SPECIFIC APOPTOSIS SIARN TO DECREASE THE EXPRESSION OF PROINFLAMATORY CITOCINES FOR THE TREATMENT OF SEPSIS
AR060788A1
(en)
An aqueous composition containing bromhexine, wherein the composition has an amount of sugar-alcohols less than 10 g based on 100 ml of the composition; and its use for secretory therapy in acute and chronic bronchopulmonary diseases.
Compounds derived from substituted pyridazine; hedgehog and smo signaling inhibitors; pharmaceutical composition; and use for the treatment of disorders or syndromes associated with hyperproliferative diseases.
Compounds derived from imidazolidin-2-one, with inhibitory activity of 17alpha-hydroxylase / lyase-c17,20; pharmaceutical composition comprising them; and use in the treatment of inflammation or cancer, among others.
Pharmaceutical composition comprising a) an activatable pharmaceutical agent, b) a plasmonic active agent; Useful for the treatment of cell proliferation disorders.
Compounds derived from thienopyrimidines, knase inhibitors mnk1 / mnk2; pharmaceutical composition; and its use for the treatment or prophylaxis of metabolic diseases, such as diabetes, kidney damage, cancer, inflammatory diseases, among others.
Compounds derived from triazolopyridine; pde10a inhibitors; obtaining process; pharmaceutical composition; and use in the treatment or prophylaxis of psychotic disorders, schizophrenia, anxiety, among other diseases.
Topical ophthalmological pharmaceutical composition comprising regorafenib, which is suspended in a pharmaceutically acceptable vehicle; manufacturing procedure and its use to treat or prevent an ophthalmological disorder.
Compounds derived from dicyano-pyridine, selective agonists of adenosine a1, for use in a procedure for the treatment and / or prophylaxis of glaucoma, normotensive glaucoma, ocular hypertension and / or combinations thereof; and pharmaceutical composition comprising one of said compounds.